keyword
https://read.qxmd.com/read/22171604/risk-evaluation-and-mitigation-strategies-rems-educating-the-prescriber
#21
REVIEW
Susan C Nicholson, Janet Peterson, Behin Yektashenas
The US FDA Amendments Act of 2007 was signed into law on 27 September 2007. A provision of this law granted the FDA new powers to enhance drug safety by requiring the pharmaceutical industry to develop Risk Evaluation and Mitigation Strategies (REMS). REMS are deemed necessary when a question exists as to whether the benefits of a drug outweigh its risks. REMS constitute a safety plan with several potential components, including a medication guide, a communication plan, elements to ensure safe use and an implementation system to help guide the prescribers, pharmacists and patients...
February 1, 2012: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://read.qxmd.com/read/21434943/the-development-of-romiplostim-for-patients-with-immune-thrombocytopenia
#22
REVIEW
Graham Molineux
Comprised of peptide and carrier components in an overall structure superficially resembling an antibody, romiplostim is the prototype of a new class of protein therapeutics called peptibodies. Romiplostim (AMG 531, Nplate) was designed to evade the immune response to recombinant thrombopoietin and offer a new method of treatment for patients with immune thrombocytopenia (ITP), an "orphan" disease. In contrast with agents designed to suppress immune function or hinder the processes of platelet destruction, romiplostim works by stimulating the production of new platelets...
March 2011: Annals of the New York Academy of Sciences
https://read.qxmd.com/read/21381287/-romiplostim-an-advance-in-the-treatment-of-idiopathic-thrombocytopenic-purpura
#23
JOURNAL ARTICLE
M E Mingot Castellano
Primary Immune thrombocytopenia or idiopathic thrombocytopenic purpura (ITP) is an acquired immune disorder presenting with abnormal hemorrhagic symptoms resulting from a decrease in the number of platelets. The disorder used to be attributed to increased destruction of platelets mediated by antibodies. In the past few years, the description of its etiopathology has changed. A deficiency in the marrow production of thrombocytes has been demonstrated; because it is associated with increased peripheral platelet destruction, the deficiency cannot be compensated...
December 2010: Methods and Findings in Experimental and Clinical Pharmacology
https://read.qxmd.com/read/21346379/infection-related-transient-loss-of-response-and-other-early-side-effects-in-chronic-itp-during-treatment-with-thrombopoietin-mimetics
#24
JOURNAL ARTICLE
Oliver Meyer, Abdulgabar Salama
BACKGROUND: The new thrombopoietin mimetics (TM) romiplostim (Nplate®) and eltrombopag (Revolade®) have been demonstrated to increase platelet counts in the majority of patients with chronic autoimmune thrombocytopenia (ITP). Platelet counts in chronic ITP may fluctuate significantly due to infections, but it is unknown if this holds true in patients being treated with TM. PATIENTS AND METHODS: 13 adult patients with refractory chronic ITP were treated with the new TM...
2011: Onkologie
https://read.qxmd.com/read/21052951/thrombopoietin-factors
#25
REVIEW
Ping Wei
Megakaryopoiesis and thrombopoiesis are the central biological processes of platelet generation. Severe thrombocytopenia is a major morbidity and mortality factor in several diseases and represents a significant unmet medical need. Since the discovery of thrombopoietin (TPO) as the primary physiological regulator of megakaryopoiesis, a number of therapeutics have been developed for thrombocytopenia and been tested in preclinical models and human clinical trials. The TPO mimetics romiplostim (Nplate(®) or AMG531) and eltrombopag (Promacta(®)) have recently been approved for the treatment of adult chronic idiopathic (immune) thrombocytopenic purpura (ITP) and are successful examples of these endeavors...
2011: Cancer Treatment and Research
https://read.qxmd.com/read/20410910/increasing-platelets-without-transfusion-is-it-time-to-introduce-novel-thrombopoietic-agents-in-neonatal-care
#26
JOURNAL ARTICLE
H Sallmon, R K Gutti, F Ferrer-Marin, Z-J Liu, M C Sola-Visner
The Food and Drug Administration recently approved two novel thrombopoiesis-stimulating agents, Romiplostim (AMG-531, Nplate) and Eltrombopag (Promacta), for the treatment of adults with immune thrombocytopenic purpura. For physicians taking care of critically ill neonates, this offers the opportunity of decreasing platelet transfusions and potentially improving the outcomes of neonates with severe and prolonged thrombocytopenia. However, several developmental factors need to be taken into consideration. First, the population of thrombocytopenic neonates likely to benefit from these agents needs to be carefully selected...
December 2010: Journal of Perinatology: Official Journal of the California Perinatal Association
https://read.qxmd.com/read/19843480/romiplostim-in-chronic-immune-thrombocytopenic-purpura
#27
REVIEW
Robert J Cersosimo
BACKGROUND: Immune thrombocytopenic purpura (ITP) is characterized by platelet deficiency due to platelet destruction and/or inadequate production. Initial therapy consists of corticosteroids or intravenous immunoglobulin (IVIg). Patients with chronic refractory disease might undergo splenectomy. Although there is no treatment of choice in those who do not respond to splenectomy, immunosuppressive agents are typically prescribed. Romiplostim is the first available drug in a recently developed class of agents that work through stimulation of the thrombopoietin (TPO) receptor (c-Mpl) to increase platelet production...
September 2009: Clinical Therapeutics
https://read.qxmd.com/read/19711585/romiplostim-for-the-treatment-of-chronic-immune-idiopathic-thrombocytopenic-purpura
#28
RANDOMIZED CONTROLLED TRIAL
Faranak Jamali, Steven Lemery, Kassa Ayalew, Suzanne Robottom, Kathy Robie-Suh, Dwaine Rieves, Richard Pazdur
PURPOSE: On August 22, 2008, Romiplostim (Nplate for Injection) received approval from the US Food and Drug Administration (FDA) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. This report summarizes the FDA analyses of the clinical data supporting this approval. EXPERIMENTAL DESIGN: The FDA reviewed data from two double-blind, placebo-controlled clinical studies, an uncontrolled extension study, and supportive studies...
July 2009: Oncology (Williston Park, NY)
https://read.qxmd.com/read/19343229/eltrombopag-in-chronic-idiopathic-thrombocytopenic-purpura-and-hcv-related-thrombocytopenia
#29
REVIEW
Simon Panzer
Platelets play a pivotal role in maintaining hemostatic competence. Thrombocytopenia, irrespective of its etiology, is associated with a risk for bleeding. Treatment modalities for chronic idiopathic thrombocytopenic purpura (ITP) are numerous, but the response is variable, often disappointing and associated with high risks. Better understanding of the pathophysiology of chronic ITP, indicating impaired platelet production rather than simply increased turnover, led to clinical trials aimed at increasing platelet production with thrombopoietin receptor agonists...
February 2009: Drugs of Today
https://read.qxmd.com/read/19197233/two-new-drugs-for-chronic-itp
#30
REVIEW
(no author information available yet)
Romiplostim (Nplate - Amgen), a recombinant fusion protein injected subcutaneously, and eltrombopag (Promacta - GlaxoSmithKline), a non-peptide taken orally, have been approved by the FDA for treatment of chronic immune thrombocytopenic purpura (ITP) refractory to corticosteroids, immunoglobulins and/or splenectomy.
February 9, 2009: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/18974747/romiplostim
#31
Douglas B Cines, Uma Yasothan, Peter Kirkpatrick
In August 2008, romiplostim (Nplate; Amgen), a thrombopoietin receptor agonist, was approved by the US FDA for the treatment of thrombocytopaenia in patients with chronic immune thrombocytopaenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
November 2008: Nature Reviews. Drug Discovery
https://read.qxmd.com/read/18211568/new-drugs-for-familiar-therapeutic-targets-thrombopoietin-receptor-agonists-and-immune-thrombocytopenic-purpura
#32
REVIEW
David J Kuter
Various agents to treat immune thrombocytopenic purpura (ITP) have been developed on the principle that stimulating the thrombopoietin (TPO) receptor would increase platelet production. First-generation agents--recombinant human thrombopoietin (rHuTPO) and pegylated recombinant human megakaryocyte growth and development factor (PEG rHuMGDF)--showed promise, but observations of antibody formation to PEG rHuMGDF led to the discontinuation of development of both agents. Second-generation agents--the TPO peptide mimetics, TPO non-peptide mimetics, and TPO agonist antibodies--have been developed to reduce or eliminate the problem of antigenicity...
February 2008: European Journal of Haematology. Supplementum
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.